Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10871623 | 0.97 | ALDH1A1 (0.46) | ALDH1A1GAAMGAMSIMGAM2 | |
| SCHEMBL370133 | 0.97 | — | — | |
| SCHEMBL17222822 | 0.94 | ALDH1A1 (0.48) | ALDH1A1GAAMGAMSIMGAM2 | |
| SCHEMBL27516509 | 0.94 | ALDH1A1 (0.48) | ALDH1A1GAAMGAMSIMGAM2 | |
| SCHEMBL11829443 | 0.94 | ALDH1A1 (0.48) | ALDH1A1GAAMGAMSIMGAM2 | |
| Hydrochloric Acid SCHEMBL22747736 | 0.94 | ALDH1A1 (0.48) | ALDH1A1GAAMGAMSIMGAM2 | |
| Sulfuric Acid SCHEMBL5416919 | 0.89 | ALDH1A1 (0.40) | ALDH1A1GAATSHRPOLBMEN1 | |
| Ammonia Solution, Strong SCHEMBL7633955 | 0.87 | ALDH1A1 (0.53) | ALDH1A1GAAMGAMSIMGAM2 | |
| Ammonia Solution, Strong SCHEMBL6537012 | 0.87 | ALDH1A1 (0.53) | ALDH1A1GAAMGAMSIMGAM2 | |
| Phosphoric Acid SCHEMBL28654659 | 0.86 | ALDH1A1 (0.42) | ALDH1A1GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624501-A | Polycarboxylate superplasticizer and preparation method thereof | 科之杰新材料集团有限公司 | 2024-03-01 | — | — | CN | claimed |
| US-20090060848-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | JOSHI YATINDRA | 2009-03-05 | — | — | US | claimed |
| US-20070148247-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA | 2007-06-28 | — | — | US | claimed |
| US-20040042964-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2004-03-04 | — | — | US | claimed |
| US-20020187192-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2002-12-12 | — | — | US | claimed |
| WO-2002087558-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | NOVARTIS AG (CH) | 2002-11-07 | — | — | WO | claimed |
| US-6462005-B1 | AQUEOUS SOLUTION CONTAINING A QUARTERNARY AMMONIUM SALT, A FLUORO COMPOUND AND OPTIONALLY AN ORGANIC SOLVENT; PROTECTING DEPOSITION FILM TO BE REMOVED; NO CORROSION OF CONDUCTIVE LAYER BEING DECONTAMINATED | TEXAS INSTRUMENTS INCORPORATED | 2002-10-08 | — | — | US | claimed |
| EP-4081215-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727923-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102428-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | UAB RES FOUND (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260097023-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND FAMOTIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN AND/OR UPSET STOMACH | SCHABAR RES ASSOCIATES LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| US-5334612-A | Solid, semisolid, solution, suspension or emulsion dosage unit | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-08-02 | — | — | US | disclosed |
| US-5284861-A | Blended with deprenyl and biperiden; muscle relaxant | ASTA MEDICA AG (DE) | 1994-02-08 | — | — | US | disclosed |
| US-5271946-A | Controlled release azelastine-containing pharmaceutical compositions | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1993-12-21 | — | — | US | disclosed |
| US-5162346-A | And associated dieeases such as neuralgia, arthritis, headaches, post-operative disability, parkinson*s disorder | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1992-11-10 | — | — | US | disclosed |
| US-5110814-A | Antiinflammatory agents; ulcerative colitis | ASTA PHARMA AG (DE) | 1992-05-05 | — | — | US | disclosed |
| US-5084481-A | 6,8-dimercaptooctanoic acid and salts for rheumatic diseases | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4486280-A | QUATERNANRY ALKYL AMMONIUM SALT OF ALPHA, BETA-UNSATURATED ACID | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1984-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102428-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | SOD1, CUTA, SOD3 | ALDH1A1 2143/4885GAA 1090/4885MGAM 1591/4885 |
| US-20260097023-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND FAMOTIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN AND/OR UPSET STOMACH | SI, TNNC1, SLC10A2 | ALDH1A1 2402/4885GAA 1078/4885MGAM 1772/4885 |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | CD47, SLC11A2, G6PD | ALDH1A1 873/4885GAA 3614/4885MGAM 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.